Targeting MicroRNAs in the perioperative window to prevent surgery-induced metastasis and postoperative cancer recurrence
Abstract
Surgery remains a central curative treatment for many solid tumors; however, postoperative recurrence and distant metastasis continue to limit long-term survival. The perioperative period is increasingly recognised as a biologically active window during which surgical trauma, inflammation, wound repair, hypoxia, platelet activation, immunosuppression, anaesthetic exposure, and extracellular vesicle signalling may influence the survival and outgrowth of residual tumour cells, circulating tumour cells, and dormant micrometastases. MicroRNAs are particularly relevant in this context because they regulate coordinated gene networks involved in tumor survival, epithelial–mesenchymal plasticity, angiogenesis, immune escape, and metastatic niche formation. OncomiRs such as miR-21, miR-10b, miR-155, miR-210, and miR-221/222 may promote recurrence-associated signaling, whereas tumor-suppressive miRNAs including miR-34a, the miR-200 family, let-7, miR-126, miR-143/145, and miR-29 may restrict metastatic progression. This review provides a translational framework linking surgery-induced host responses with miRNA-mediated metastatic regulation. It discusses perioperative immune and stromal remodeling, anesthetic and analgesic influences, exosomal miRNAs, biomarker-guided monitoring, therapeutic delivery systems, safety concerns, and clinical trial design. Although perioperative miRNA therapy is not yet a validated clinical intervention, serial miRNA profiling combined with ctDNA, circulating tumor cells, cytokines, and clinicopathological variables may support future precision strategies to identify high-risk patients and guide recurrence-prevention studies. The key challenge is to suppress pro-metastatic signaling without impairing wound healing, infection control, or postoperative recovery.
Related
- Predictive value of preoperative [18F]FDG PET/CT imaging parameters for postoperative recurrence and metastasis in breast cancer patients
- LncRNA MKRN3-AS1 promotes metastasis and autophagy of hepatocellular carcinoma by sponging multiple microRNAs
- WITHDRAWN: Connecting Baseline Immune Exhaustion in Hot Tumors to Oral Cancer Recurrence and Nodal Metastasis
- Protocol for an immunocompetent KPC mouse model of pancreatic cancer resection and recurrence for perioperative treatment studies.
- Pregnancy Complicated by Citrin Deficiency and Gestational Diabetes Mellitus: Perioperative Metabolic Management and Postoperative Analgesic Challenges Following Caesarean Delivery
BibTeX
@article{yao2026targeting,
title = {{Targeting MicroRNAs in the perioperative window to prevent surgery-induced metastasis and postoperative cancer recurrence}},
author = {Bin Yao and Binsong Qiu and Yin Zhang and Wei Feng},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1970621},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1970621},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting MicroRNAs in the perioperative window to prevent surgery-induced metastasis and postoperative cancer recurrence
AU - Bin Yao
AU - Binsong Qiu
AU - Yin Zhang
AU - Wei Feng
PY - 2026
DA - 2026/11/06
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1970621
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1970621
AB - Surgery remains a central curative treatment for many solid tumors; however, postoperative recurrence and distant metastasis continue to limit long-term survival. The perioperative period is increasingly recognised as a biologically active window during which surgical trauma, inflammation, wound repair, hypoxia, platelet activation, immunosuppression, anaesthetic exposure, and extracellular vesicle signalling may influence the survival and outgrowth of residual tumour cells, circulating tumour cells, and dormant micrometastases. MicroRNAs are particularly relevant in this context because they regulate coordinated gene networks involved in tumor survival, epithelial–mesenchymal plasticity, angiogenesis, immune escape, and metastatic niche formation. OncomiRs such as miR-21, miR-10b, miR-155, miR-210, and miR-221/222 may promote recurrence-associated signaling, whereas tumor-suppressive miRNAs including miR-34a, the miR-200 family, let-7, miR-126, miR-143/145, and miR-29 may restrict metastatic progression. This review provides a translational framework linking surgery-induced host responses with miRNA-mediated metastatic regulation. It discusses perioperative immune and stromal remodeling, anesthetic and analgesic influences, exosomal miRNAs, biomarker-guided monitoring, therapeutic delivery systems, safety concerns, and clinical trial design. Although perioperative miRNA therapy is not yet a validated clinical intervention, serial miRNA profiling combined with ctDNA, circulating tumor cells, cytokines, and clinicopathological variables may support future precision strategies to identify high-risk patients and guide recurrence-prevention studies. The key challenge is to suppress pro-metastatic signaling without impairing wound healing, infection control, or postoperative recovery.
SN - 1663-9812
ER -